Otahal and his team proved that fluvastatin or pitavastatin combined with erlotinib led to apoptosis in human lung adenocarcinoma cells with a mutated or overexpressed epidermal growth factor receptor (EGFR) [38,39,40]. The gene discussed is EGFR; the disease is lung adenocarcinoma.